S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Intellipharmaceutics Updates Developments on Its Rexista(TM) Oxycodone Technology ()|
|Ventrus Biosciences Announces Positive Results From Clinical Dermal Safety and Pharmacokinetic Studies of Diltiazem (VEN 307) (2013/9/11)|
|Maxim Power Corp. Announces 2013 Third Quarter Financial and Operating Results (2013/11/7)|
|Spectrum Pharmaceuticals Reports Financial Results for Second Quarter 2013 ()|
|Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders (2013/9/3)|
|Theravance Announces Positive Results From Phase 2b Study 0091 With Its LAMA Candidate, TD-4208, for the Treatment of COPD (2013/9/4)|
|Oncolytics Biotech Inc. Collaborators to Present Positive Clinical Trial Data at the 15th Annual World Conference on Lung Cancer (2013/10/1)|
|BNY Mellon Reports Third Quarter Earnings Of $967 Million Or $0.82 Per Common Share; Earnings Per Share Of $0.60 Excluding The Benefit Related To A Recent U.S. Tax Court Decision (a) (2013/10/16)|
|Oncolytics Biotech® Inc. Collaborators Present Positive Data Correlating Specific Biomarkers with Survival in NSCLC Patients Treated with REOLYSIN®, Carboplatin and Paclitaxel (2013/10/28)|
|Financial Engines Reports Third Quarter 2013 Financial Results (2013/11/5)|
Click above to view more mutual fund data and stats for auc - AusGold Limited.